Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.3%

1 terminated out of 19 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

7%

1 of 15 completed with results

Key Signals

1 with results94% success

Data Visualizations

Phase Distribution

16Total
P 1 (12)
P 2 (1)
P 3 (2)
P 4 (1)

Trial Status

Completed15
Withdrawn2
Terminated1
Not Yet Recruiting1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT06628076Not Yet Recruiting

Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated from Patients with Hospital Acquired Infections in Sohag University Hospitals, Egypt

NCT04600752Phase 4Completed

Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India

NCT02688361Phase 1CompletedPrimary

A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution

NCT02730364Phase 3WithdrawnPrimary

An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu

NCT02678234Phase 3WithdrawnPrimary

An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

NCT01772238Phase 1CompletedPrimary

Bioequivalence Study of an Amoxicillin-Clavulanic

NCT00354965Phase 1CompletedPrimary

Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients

NCT02000765Phase 1CompletedPrimary

A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects

NCT02257398Phase 1CompletedPrimary

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

NCT01767584Phase 1CompletedPrimary

Bioequivalence Study of Cephalexin Tablets 1g

NCT01767532Phase 1CompletedPrimary

Bioequivalence Study of Cephalexin Suspension 125

NCT02202187Phase 1CompletedPrimary

A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers

NCT01767571Phase 1CompletedPrimary

Bioequivalence Study of Cephalexin Suspension 250

NCT02169583Phase 1CompletedPrimary

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

NCT01615796Phase 1CompletedPrimary

Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses

NCT01706315Phase 1CompletedPrimary

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

NCT01353768CompletedPrimary

Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study

NCT01292213TerminatedPrimary

A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom

NCT01510938Phase 2CompletedPrimary

Probiotics in Respiratory Tract Infections in Children

Showing all 19 trials

Research Network

Activity Timeline